Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, posted on LinkedIn:
”New in ATVB (Nov 2025)
Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
In >11,800 post-ACS patients from ODYSSEY OUTCOMES, a 9-plex mass-spectrometry apolipoprotein panel outperformed the standard lipid profile in predicting:
• Major adverse cardiovascular events (MACE) (AUC 0.65 vs 0.58)
• All-cause death (AUC 0.70 vs 0.60)
The panel also identified which patients benefit most from PCSK9 inhibition (alirocumab) – paving the way for precision lipidology.
Key components: Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, ApoE.
Alirocumab reduced Apo(a), ApoB, and ApoC isoforms by >30–50%.
Bottom line:
Integrated apolipoprotein profiling refines risk stratification and optimizes treatment allocation – a step forward in personalized cardiovascular medicine.
Open Access”
Title: Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Authors: Esther Reijnders, Patrick M. Bossuyt, J. Wouter Jukema, L. Renee Ruhaak, Fred P.H.T.M. Romijn, Michael Szarek, Stella Trompet, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Sergio Fazio, Irena Stevanovic, Shaun G. Goodman, Robert A. Harrington, Harvey D. White, Philippe Gabriel Steg, Gregory G. Schwartz, Christa M. Cobb
Stay informed with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology